ProCE Banner Activity

CE / CME

What to Know About Each FDA-Approved Agent for Spinal Muscular Atrophy

Clinical Thought
With 3 FDA-approved agents now available for SMA, here’s my summary of the most clinically important information to help you educate families and assist them in making decisions about treatment.

Registered Nurses AANP : 0.25 AANP contact {hour}

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

Released: October 23, 2020

Expiration: October 22, 2021

No longer available for credit.

Share

Faculty

Nancy L. Kuntz

Nancy L. Kuntz, MD

Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Medical Director
Mazza Foundation Neuromuscular Disorders Program
Ann & Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Biogen

Genentech, a member of the Roche Group

Target Audience

This program is intended for neurologists, pediatricians, hospitalists, primary care physicians, nurse practitioners, physician assistants, and other healthcare professionals who care for patients with SMA.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess the safety and efficacy profiles of currently available and emerging agents for the management of SMA

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Nancy L. Kuntz, MD

Professor of Pediatrics and Neurology
Northwestern University Feinberg School of Medicine
Medical Director
Mazza Foundation Neuromuscular Disorders Program
Ann & Robert H. Lurie Childrens Hospital of Chicago
Chicago, Illinois

Nancy L. Kuntz, MD, has disclosed that she has received consulting fees from AveXis, Biogen, Cytokinetics, and Genentech.

Staff Disclosure

Staff

Megan Cartwright, PhD

Senior Clinical Editor

Megan Cartwright, PhD, has no relevant conflicts of interest to report.

Anne Roc, PhD

Director, Scientific Services

Anne Roc, PhD, has no relevant conflicts of interest to report.

Zachary Schwartz, MSc, ELS

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Julie Skowronski, FNP-BC

Julie Skowronski, FNP-BC, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Clinical Care Options, LLC (CCO) and the National Association of Pediatric Nurse Practitioners . Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation Statement

This program is accredited for 0.25 NAPNAP CE contact hours of which 0.25 contain pharmacology content, per the National Association of Pediatric Nurse Practitioners Continuing Education Guidelines.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 23, 2020, through October 22, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 100% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to increase the knowledge and competence of clinicians and healthcare providers in the recognition, assessment, diagnosis, and management of patients with SMA to improve patient outcomes.